2025-12-19 - Analysis Report
Okay, here's a comprehensive analysis of NVDA based on the provided data, broken down into sections as requested:

**0) Report in English:**

**1) Return Rate Comparison & Alpha/Beta Analysis:**

*   **Ticker:** NVDA (NVIDIA Corp)
*   **Overview:** NVIDIA is a leading designer of graphics processing units (GPUs) that power gaming and professional visualization, and increasingly, data center and automotive applications.
*   **NVDA Cumulative Return:** 944.38%
*   **S&P 500 (VOO) Cumulative Return:** 99.09%
*   **Divergence:** 845.29 (Relative Divergence: 74.9)

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD   | Alpha   | Beta | Cap(B) |
|------------|----------|-------|---------|------|--------|
| 2015-2017  | 278.0%   | 74.6% | 249.0%  | -0.0 | 117.8  |
| 2016-2018  | 69.0%    | 77.4% | 54.0%   | 0.0 | 81.3   |
| 2017-2019  | 20.0%    | 77.4% | -2.0%   | 0.2 | 143.2  |
| 2018-2020  | -83.0%   | 78.4% | -107.0% | 0.2 | 317.9  |
| 2019-2021  | 427.0%   | 78.4% | 381.0%  | 0.5 | 716.1  |
| 2020-2022  | 19.0%    | 79.6% | 19.0%   | 0.5 | 355.8  |
| 2021-2023  | 186.0%   | 79.6% | 184.0%  | 0.6 | 1205.7 |
| 2022-2024  | 439.0%   | 79.6% | 418.0%  | 0.6 | 3269.6 |
| 2023-2025  | 678.0%   | 80.3% | 614.0%  | 0.6 | 4239.8 |

**Analysis:**

*   NVDA has significantly outperformed the S&P 500 over the provided period. The cumulative return is nearly ten times greater. The relative divergence of 74.9 suggests that, while still strong, the recent outperformance isn't at its historical peak.
*   The Alpha values are consistently high, indicating NVDA's returns are largely independent of the market. The Beta values, while low, show a slight increasing trend, suggesting NVDA's price is becoming more sensitive to overall market movements.
*   CAGR is extremely high, but the MDD values are also high and very consistent, indicating high volatility and potential for significant drawdowns.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 174.14
*   **Previous Close:** 170.94
*   **Change:** 1.87
*   **5-day SMA:** 174.82
*   **20-day SMA:** 179.64
*   **60-day SMA:** 185.82

**Analysis:**

*   NVDA's current price is below its 5-day, 20-day, and 60-day Simple Moving Averages (SMA). This *could* indicate a short-term downtrend or pullback.
*   The recent price increase of 1.87 could signal a short term rebound.

**3) RSI, PPO & Expected Return:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment Recommended)
*   **RSI:** 45.97
*   **PPO:** -0.3991
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80) (Cash Ratio: 0% on 2025-12-09)
*   **Recent (20 days) Relative Divergence Change:** -3.2 (Short-term decline)
*   **Expected Return (%):** 251.3%

**Analysis:**

*   The MRI suggests a medium level of investment risk.
*   The RSI is below 50, suggesting that NVDA is neither overbought nor oversold. The stock is in a neutral position.
*   The negative PPO suggests that the short-term moving average is below the long-term moving average, which could point to further downward momentum.
*   The Hybrid Signal suggesting buying 90% with cash and 0% cash ratio indicates a positive short-term outlook.
*   A recent decrease in relative divergence indicates a short-term decline.
*   The extremely high Expected Return suggests that analysts believe NVDA has strong long-term growth potential.

**4) Recent News & Significant Events:**

*   **Mixed Sentiment:** The news articles paint a mixed picture.
    *   Some articles highlight potential risks (e.g., "Nvidia's Depreciation Time Bomb," concerns about CoreWeave/Oracle's financial health).
    *   Others are positive, focusing on rating upgrades ("Early Christmas Gift for Investors") and rebounds ("NVDA Holds Near $174 After CPI-Fueled Tech Rebound").
    *   One article notes Eli Lilly is outperforming NVDA recently, suggesting potential shifting market leadership.
    *   One article suggests that NVDA shares are down 3.8%.

**4-2) Analyst Opinions:**

*   **Consensus:** Strong Buy (Mean: 1.33)
*   **Opinions:** 56
*   **Target Price:** Average: 250.93 / High: 352.00 / Low: 140.00

**Analysis:**

*   Analyst consensus is overwhelmingly positive with a "Strong Buy" rating and many opinions.
*   The average target price suggests significant upside potential from the current price of 174.14.
*   However, the wide range between the high and low target prices (140 to 352) indicates considerable uncertainty and differing opinions about NVDA's future performance.

**5) Comprehensive Analysis (Summary):**

NVDA presents a complex picture. On one hand:

*   **Exceptional Historical Performance:** It has dramatically outperformed the S&P 500.
*   **Strong Analyst Support:**  Analysts have a Strong Buy consensus and expect significant upside.
*    **High Growth Potential:** The high expected return suggests long-term growth.

However:

*   **High Volatility:**  The high MDD indicates significant price swings.
*   **Potential Downtrend:**  The price is below its SMAs, the PPO is negative, and the recent divergence change is negative.
*   **Mixed News:** Recent news highlights both opportunities and risks. The "Depreciation Time Bomb" article raises concerns about the financial health of some of NVIDIA's customers.
*   **Shifting Market Leadership:** The comparison to Eli Lilly suggests a potential shift in market leadership.

**Conclusion:**

NVDA appears to be a high-growth, high-volatility stock with strong long-term potential. The recent pullback and mixed news warrant caution. Investors should carefully consider their risk tolerance and do further research before investing.  The current MRI rating of 0.7 suggests a medium investment recommendation.  The recent negative short-term divergence suggests further monitoring is necessary. Overall, NVDA appears to be an attractive investment for the long-term, but it is important to be aware of the potential risks.



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.